 | • レポートコード：MRC2312MG09841 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のCD51抗体市場規模と予測を収録しています。・世界のCD51抗体市場：売上、2018年-2023年、2024年-2029年 ・世界のCD51抗体市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のCD51抗体市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「モノクローナル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 CD51抗体のグローバル主要企業は、Merck、 GeneTex、 Bioss、 Cell Sciences、 BioLegend、 RayBiotech、 Bio-Rad、 Thermo Fisher Scientific、 BD Biosciences、 BosterBio、 Enzo Life Sciences、 LifeSpan BioSciences、 Leinco Technologies、 Antigenix America Inc.、 R&D Systems、 Novus Biologicals、 Miltenyi Biotec、 SouthernBiotech、 Biobyt、 Jingjie PTM BioLabなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、CD51抗体のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のCD51抗体市場：タイプ別、2018年-2023年、2024年-2029年 世界のCD51抗体市場：タイプ別市場シェア、2022年 ・モノクローナル、ポリクローナル 世界のCD51抗体市場：用途別、2018年-2023年、2024年-2029年 世界のCD51抗体市場：用途別市場シェア、2022年 ・免疫化学（IHC）、免疫蛍光（IF）、免疫沈降（IP）、ウェスタンブロット（WB）、ELISA、その他 世界のCD51抗体市場：地域・国別、2018年-2023年、2024年-2029年 世界のCD51抗体市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるCD51抗体のグローバル売上、2018年-2023年 ・主要企業におけるCD51抗体のグローバル売上シェア、2022年 ・主要企業におけるCD51抗体のグローバル販売量、2018年-2023年 ・主要企業におけるCD51抗体のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Merck、 GeneTex、 Bioss、 Cell Sciences、 BioLegend、 RayBiotech、 Bio-Rad、 Thermo Fisher Scientific、 BD Biosciences、 BosterBio、 Enzo Life Sciences、 LifeSpan BioSciences、 Leinco Technologies、 Antigenix America Inc.、 R&D Systems、 Novus Biologicals、 Miltenyi Biotec、 SouthernBiotech、 Biobyt、 Jingjie PTM BioLab ************************************************************* ・調査・分析レポートの概要 CD51抗体市場の定義 市場セグメント 世界のCD51抗体市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のCD51抗体市場規模 世界のCD51抗体市場規模：2022年 VS 2029年 世界のCD51抗体市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのCD51抗体の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のCD51抗体製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：モノクローナル、ポリクローナル CD51抗体のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：免疫化学（IHC）、免疫蛍光（IF）、免疫沈降（IP）、ウェスタンブロット（WB）、ELISA、その他 CD51抗体の用途別グローバル売上・予測 ・地域別市場分析 地域別CD51抗体市場規模 2022年と2029年 地域別CD51抗体売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Merck、 GeneTex、 Bioss、 Cell Sciences、 BioLegend、 RayBiotech、 Bio-Rad、 Thermo Fisher Scientific、 BD Biosciences、 BosterBio、 Enzo Life Sciences、 LifeSpan BioSciences、 Leinco Technologies、 Antigenix America Inc.、 R&D Systems、 Novus Biologicals、 Miltenyi Biotec、 SouthernBiotech、 Biobyt、 Jingjie PTM BioLab ... |
This research report provides a comprehensive analysis of the CD51 Antibody market, focusing on the current trends, market dynamics, and future prospects. The report explores the global CD51 Antibody market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of CD51 Antibody, challenges faced by the industry, and potential opportunities for market players.
The global CD51 Antibody market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The CD51 Antibody market presents opportunities for various stakeholders, including Immunochemistry (IHC), Immunofluorescence (IF). Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in CD51 Antibody market. Additionally, the growing consumer demand present avenues for market expansion.
The global CD51 Antibody market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the CD51 Antibody market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the CD51 Antibody market.
Market Overview: The report provides a comprehensive overview of the CD51 Antibody market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal, Polyclonal), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the CD51 Antibody market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the CD51 Antibody market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the CD51 Antibody market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the CD51 Antibody market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the CD51 Antibody market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the CD51 Antibody market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for CD51 Antibody, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the CD51 Antibody market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
CD51 Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Monoclonal
Polyclonal
Market segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
Global CD51 Antibody Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Merck
GeneTex
Bioss
Cell Sciences
BioLegend
RayBiotech
Bio-Rad
Thermo Fisher Scientific
BD Biosciences
BosterBio
Enzo Life Sciences
LifeSpan BioSciences
Leinco Technologies
Antigenix America Inc.
R&D Systems
Novus Biologicals
Miltenyi Biotec
SouthernBiotech
Biobyt
Jingjie PTM BioLab
Outline of Major Chapters:
Chapter 1: Introduces the definition of CD51 Antibody, market overview.
Chapter 2: Global CD51 Antibody market size in revenue.
Chapter 3: Detailed analysis of CD51 Antibody company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CD51 Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 CD51 Antibody Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CD51 Antibody Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CD51 Antibody Overall Market Size
2.1 Global CD51 Antibody Market Size: 2022 VS 2029
2.2 Global CD51 Antibody Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CD51 Antibody Players in Global Market
3.2 Top Global CD51 Antibody Companies Ranked by Revenue
3.3 Global CD51 Antibody Revenue by Companies
3.4 Top 3 and Top 5 CD51 Antibody Companies in Global Market, by Revenue in 2022
3.5 Global Companies CD51 Antibody Product Type
3.6 Tier 1, Tier 2 and Tier 3 CD51 Antibody Players in Global Market
3.6.1 List of Global Tier 1 CD51 Antibody Companies
3.6.2 List of Global Tier 2 and Tier 3 CD51 Antibody Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global CD51 Antibody Market Size Markets, 2022 & 2029
4.1.2 Monoclonal
4.1.3 Polyclonal
4.2 By Type – Global CD51 Antibody Revenue & Forecasts
4.2.1 By Type – Global CD51 Antibody Revenue, 2018-2023
4.2.2 By Type – Global CD51 Antibody Revenue, 2024-2029
4.2.3 By Type – Global CD51 Antibody Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global CD51 Antibody Market Size, 2022 & 2029
5.1.2 Immunochemistry (IHC)
5.1.3 Immunofluorescence (IF)
5.1.4 Immunoprecipitation (IP)
5.1.5 Western Blot (WB)
5.1.6 ELISA
5.1.7 Others
5.2 By Application – Global CD51 Antibody Revenue & Forecasts
5.2.1 By Application – Global CD51 Antibody Revenue, 2018-2023
5.2.2 By Application – Global CD51 Antibody Revenue, 2024-2029
5.2.3 By Application – Global CD51 Antibody Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global CD51 Antibody Market Size, 2022 & 2029
6.2 By Region – Global CD51 Antibody Revenue & Forecasts
6.2.1 By Region – Global CD51 Antibody Revenue, 2018-2023
6.2.2 By Region – Global CD51 Antibody Revenue, 2024-2029
6.2.3 By Region – Global CD51 Antibody Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America CD51 Antibody Revenue, 2018-2029
6.3.2 US CD51 Antibody Market Size, 2018-2029
6.3.3 Canada CD51 Antibody Market Size, 2018-2029
6.3.4 Mexico CD51 Antibody Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe CD51 Antibody Revenue, 2018-2029
6.4.2 Germany CD51 Antibody Market Size, 2018-2029
6.4.3 France CD51 Antibody Market Size, 2018-2029
6.4.4 U.K. CD51 Antibody Market Size, 2018-2029
6.4.5 Italy CD51 Antibody Market Size, 2018-2029
6.4.6 Russia CD51 Antibody Market Size, 2018-2029
6.4.7 Nordic Countries CD51 Antibody Market Size, 2018-2029
6.4.8 Benelux CD51 Antibody Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia CD51 Antibody Revenue, 2018-2029
6.5.2 China CD51 Antibody Market Size, 2018-2029
6.5.3 Japan CD51 Antibody Market Size, 2018-2029
6.5.4 South Korea CD51 Antibody Market Size, 2018-2029
6.5.5 Southeast Asia CD51 Antibody Market Size, 2018-2029
6.5.6 India CD51 Antibody Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America CD51 Antibody Revenue, 2018-2029
6.6.2 Brazil CD51 Antibody Market Size, 2018-2029
6.6.3 Argentina CD51 Antibody Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa CD51 Antibody Revenue, 2018-2029
6.7.2 Turkey CD51 Antibody Market Size, 2018-2029
6.7.3 Israel CD51 Antibody Market Size, 2018-2029
6.7.4 Saudi Arabia CD51 Antibody Market Size, 2018-2029
6.7.5 UAE CD51 Antibody Market Size, 2018-2029
7 CD51 Antibody Companies Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck CD51 Antibody Major Product Offerings
7.1.4 Merck CD51 Antibody Revenue in Global Market (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 GeneTex
7.2.1 GeneTex Company Summary
7.2.2 GeneTex Business Overview
7.2.3 GeneTex CD51 Antibody Major Product Offerings
7.2.4 GeneTex CD51 Antibody Revenue in Global Market (2018-2023)
7.2.5 GeneTex Key News & Latest Developments
7.3 Bioss
7.3.1 Bioss Company Summary
7.3.2 Bioss Business Overview
7.3.3 Bioss CD51 Antibody Major Product Offerings
7.3.4 Bioss CD51 Antibody Revenue in Global Market (2018-2023)
7.3.5 Bioss Key News & Latest Developments
7.4 Cell Sciences
7.4.1 Cell Sciences Company Summary
7.4.2 Cell Sciences Business Overview
7.4.3 Cell Sciences CD51 Antibody Major Product Offerings
7.4.4 Cell Sciences CD51 Antibody Revenue in Global Market (2018-2023)
7.4.5 Cell Sciences Key News & Latest Developments
7.5 BioLegend
7.5.1 BioLegend Company Summary
7.5.2 BioLegend Business Overview
7.5.3 BioLegend CD51 Antibody Major Product Offerings
7.5.4 BioLegend CD51 Antibody Revenue in Global Market (2018-2023)
7.5.5 BioLegend Key News & Latest Developments
7.6 RayBiotech
7.6.1 RayBiotech Company Summary
7.6.2 RayBiotech Business Overview
7.6.3 RayBiotech CD51 Antibody Major Product Offerings
7.6.4 RayBiotech CD51 Antibody Revenue in Global Market (2018-2023)
7.6.5 RayBiotech Key News & Latest Developments
7.7 Bio-Rad
7.7.1 Bio-Rad Company Summary
7.7.2 Bio-Rad Business Overview
7.7.3 Bio-Rad CD51 Antibody Major Product Offerings
7.7.4 Bio-Rad CD51 Antibody Revenue in Global Market (2018-2023)
7.7.5 Bio-Rad Key News & Latest Developments
7.8 Thermo Fisher Scientific
7.8.1 Thermo Fisher Scientific Company Summary
7.8.2 Thermo Fisher Scientific Business Overview
7.8.3 Thermo Fisher Scientific CD51 Antibody Major Product Offerings
7.8.4 Thermo Fisher Scientific CD51 Antibody Revenue in Global Market (2018-2023)
7.8.5 Thermo Fisher Scientific Key News & Latest Developments
7.9 BD Biosciences
7.9.1 BD Biosciences Company Summary
7.9.2 BD Biosciences Business Overview
7.9.3 BD Biosciences CD51 Antibody Major Product Offerings
7.9.4 BD Biosciences CD51 Antibody Revenue in Global Market (2018-2023)
7.9.5 BD Biosciences Key News & Latest Developments
7.10 BosterBio
7.10.1 BosterBio Company Summary
7.10.2 BosterBio Business Overview
7.10.3 BosterBio CD51 Antibody Major Product Offerings
7.10.4 BosterBio CD51 Antibody Revenue in Global Market (2018-2023)
7.10.5 BosterBio Key News & Latest Developments
7.11 Enzo Life Sciences
7.11.1 Enzo Life Sciences Company Summary
7.11.2 Enzo Life Sciences Business Overview
7.11.3 Enzo Life Sciences CD51 Antibody Major Product Offerings
7.11.4 Enzo Life Sciences CD51 Antibody Revenue in Global Market (2018-2023)
7.11.5 Enzo Life Sciences Key News & Latest Developments
7.12 LifeSpan BioSciences
7.12.1 LifeSpan BioSciences Company Summary
7.12.2 LifeSpan BioSciences Business Overview
7.12.3 LifeSpan BioSciences CD51 Antibody Major Product Offerings
7.12.4 LifeSpan BioSciences CD51 Antibody Revenue in Global Market (2018-2023)
7.12.5 LifeSpan BioSciences Key News & Latest Developments
7.13 Leinco Technologies
7.13.1 Leinco Technologies Company Summary
7.13.2 Leinco Technologies Business Overview
7.13.3 Leinco Technologies CD51 Antibody Major Product Offerings
7.13.4 Leinco Technologies CD51 Antibody Revenue in Global Market (2018-2023)
7.13.5 Leinco Technologies Key News & Latest Developments
7.14 Antigenix America Inc.
7.14.1 Antigenix America Inc. Company Summary
7.14.2 Antigenix America Inc. Business Overview
7.14.3 Antigenix America Inc. CD51 Antibody Major Product Offerings
7.14.4 Antigenix America Inc. CD51 Antibody Revenue in Global Market (2018-2023)
7.14.5 Antigenix America Inc. Key News & Latest Developments
7.15 R&D Systems
7.15.1 R&D Systems Company Summary
7.15.2 R&D Systems Business Overview
7.15.3 R&D Systems CD51 Antibody Major Product Offerings
7.15.4 R&D Systems CD51 Antibody Revenue in Global Market (2018-2023)
7.15.5 R&D Systems Key News & Latest Developments
7.16 Novus Biologicals
7.16.1 Novus Biologicals Company Summary
7.16.2 Novus Biologicals Business Overview
7.16.3 Novus Biologicals CD51 Antibody Major Product Offerings
7.16.4 Novus Biologicals CD51 Antibody Revenue in Global Market (2018-2023)
7.16.5 Novus Biologicals Key News & Latest Developments
7.17 Miltenyi Biotec
7.17.1 Miltenyi Biotec Company Summary
7.17.2 Miltenyi Biotec Business Overview
7.17.3 Miltenyi Biotec CD51 Antibody Major Product Offerings
7.17.4 Miltenyi Biotec CD51 Antibody Revenue in Global Market (2018-2023)
7.17.5 Miltenyi Biotec Key News & Latest Developments
7.18 SouthernBiotech
7.18.1 SouthernBiotech Company Summary
7.18.2 SouthernBiotech Business Overview
7.18.3 SouthernBiotech CD51 Antibody Major Product Offerings
7.18.4 SouthernBiotech CD51 Antibody Revenue in Global Market (2018-2023)
7.18.5 SouthernBiotech Key News & Latest Developments
7.19 Biobyt
7.19.1 Biobyt Company Summary
7.19.2 Biobyt Business Overview
7.19.3 Biobyt CD51 Antibody Major Product Offerings
7.19.4 Biobyt CD51 Antibody Revenue in Global Market (2018-2023)
7.19.5 Biobyt Key News & Latest Developments
7.20 Jingjie PTM BioLab
7.20.1 Jingjie PTM BioLab Company Summary
7.20.2 Jingjie PTM BioLab Business Overview
7.20.3 Jingjie PTM BioLab CD51 Antibody Major Product Offerings
7.20.4 Jingjie PTM BioLab CD51 Antibody Revenue in Global Market (2018-2023)
7.20.5 Jingjie PTM BioLab Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
